| Literature DB >> 20877218 |
Wei Zhou1, Shu-Lan Su, Jin-Ao Duan, Jian-Ming Guo, Da-Wei Qian, Er-Xin Shang, Jin Zhang.
Abstract
Shixiao San is a famous Traditional Chinese Medicine (TCM) formula that has been used for a long time for the treatment of gynecological diseases. In this paper, the active constituents in Shixiao San were characterized by using bioactivity evaluation followed by UPLC-QTOF and Markerlynx analysis. The analgesic activities of two extracts of Shixiao San were evaluated using the hot-plate test, acetic acid-induced writhing and dysmenorrhea mice model. The results showed that the analgesic activity of Shixiao San vinegary extract (boiling vinegar) was superior to the aqueous extract. UPLC-QTOF and Markerlynx analytic results showed that the process of boiling in vinegar may improve the dissolution of Shixiao San flavanoids, and these flavanoids may contribute to the observed analgesic activity. This work demonstrated that UPLC/QTOFMS and Markerlynx could serve as new methods for fast generation and automated analysis of information-rich data from Chinese herbal medicines.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20877218 PMCID: PMC6257704 DOI: 10.3390/molecules15096217
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Effect of AESS and VESS on hot - plate test in mice ( ± s, n = 10)#.
| Group | Dosage (g/kg) | Hot - plate latency (s) | ||
|---|---|---|---|---|
| 1 h | 2 h | |||
| Control group | - | 15.84 ± 3.81 | 15.40 ± 3.64 | |
| Pethidine group | 0.025 | 32.37 ± 6.56** | 16.45 ± 4.11 | |
| AESS group | High dose | 4.90 | 19.71 ± 5.90 | 17.48 ± 6.74 |
| Low dose | 2.45 | 19.40 ± 3.73 | 15.40 ± 3.66 | |
| VESS group | High dose | 10.06 | 20.37 ± 3.56* | 18.33 ± 4.53 |
| Low dose | 5.03 | 20.21 ± 3.78* | 18.13 ± 5.49 | |
The crude extracts were ensured to be equal in dose converting into crude plant materials, and the doses of crude plant materials for two extracts are equal; # Values are expressed as mean ± standard deviations (n = 10); ** Level of significance relative to the control value P < 0.01; * Level of significance relative to the control value P < 0.05.
Effect of AESS and VESS on acetic acid - induced writhing movements in mice ( ± s, n = 10)#.
| Group | Dosage (g/kg) | Number of writhings | Inhibition (%) | |
|---|---|---|---|---|
| Control group | - | 56.10 ± 5.86 | - | |
| Pethidine group | 0.025 | 0.00 ** | 100.00 | |
| AESS group | High dose | 4.90 | 31.50 ± 5.19** | 43.85 |
| Low dose | 2.45 | 44.60 ± 12.06* | 20.50 | |
| VESS group | High dose | 10.06 | 29.11 ± 7.01** | 48.10 |
| Low dose | 5.03 | 32.70 ± 7.35** | 47.71 | |
The crude extracts were ensured to be equal in dose converting into crude plant materials, and the doses of crude plant materials for two extracts are equal; # Values are expressed as mean ± standard deviations (n = 10); ** Level of significance relative to the control value P < 0.01; * Level of significance relative to the control value P < 0.05.
Effects of AESS and VESS on writhing of dysmenorrhea mice models ( ± s, n = 10)#.
| Group | Dose (g/kg) | Number of writhings | Inhibition (%) | |
|---|---|---|---|---|
| Normal group | - | 0 | 100 | |
| Control group | - | 9.75 ± 3.86 | - | |
| Celecoxib group | 0.0411 | 4.73 ± 3.87* | 51.52 | |
| AESS group | High dose | 4.90 | 5.00 ± 3.02* | 48.71 |
| Low dose | 2.45 | 5.92 ± 2.93* | 39.25 | |
| VESS group | High dose | 10.06 | 4.00 ± 2.66* | 58.97 |
| Low dose | 5.03 | 3.83 ± 2.66* | 60.68 | |
The crude extracts were ensured to be equal in dose converting into crude plant materials, and the doses of crude plant materials for two extracts are equal; # Values are expressed as mean ± standard deviations (n = 10); * Level of significance relative to the control value P < 0.05.
Effects of AESS and VESS on the content of Ca2+ and NO in the uterus tissue homogenate ( ± s, n = 10)#.
| Group | Dose (g/kg) | Ca2+/ mmol·gprot-1 | NO/ μmol·gprot-1 | |
|---|---|---|---|---|
| Normal group | - | 0.08 ± 0.07 | 9.12 ± 3.24 | |
| Control group | - | 0.44 ± 0.21 | 18.62 ± 4.12 | |
| Celecoxib group | 0.0411 | 0.20 ± 0.14 | 18.73 ± 7.25 | |
| AESS group | High dose | 4.90 | 0.13 ± 0.07* | 9.15 ± 2.34* |
| Low dose | 2.45 | 0.22 ± 0.12* | 11.98 ± 3.44* | |
| VESS group | High dose | 10.06 | 0.11 ± 0.18* | 9.02 ± 2.95* |
| Low dose | 5.03 | 0.13 ± 0.11* | 10.46 ± 3.05* | |
The crude extracts were ensured to be equal in dose converting into crude plant materials, and the doses of crude plant materials for two extracts are equal; # Values are expressed as mean ± standard deviations (n = 10); * Level of significance relative to the control value P < 0.05.
Figure 1Total current chromatograms of AESS (A), VESS (B), Vinegar (C) in positive mode; and AESS (E), VESS (F), Vinegar (G) in negative mode.
UPLC - MS analytic results of AESS and VESS.
| NO. | Retention time (min) | Identification | UV λ max (nm) | ESI+ | ESI- | Source herb |
|---|---|---|---|---|---|---|
| 1 | 6.79 | unknown | 225 | - | 231 [M+H]+, 253[M+Na]+ |
|
| 2 | 8.83 | unknown | 228, 272 | - | 277 [M+H]+, 299 [M+Na]+ |
|
| 3 | 9.11 | quercetin-3- | 255, 353 | 755 [M−H]−, 300 [M−H−rha-glu-rha]−, 271 [M−2H−rha-glu-rha−CO]−, 255 [M−2H−rha-glu-rha−CO2]− | 757 [M+H]+ |
|
| 4 | 9.41 | quercetin-3- | 255, 355 | 609 [M−H]−, 300 [M−H−rha-glu]−, 271 [M−2H−rha-glu−CO]−, 255 [M−2H− rha-glu−CO2]− | 611 [M+H]+ |
|
| 5 | 9.70 | kaempferol-3- | 265, 348 | 739 [M−H]−, 284 [M−H−rha-glu-rha]−, 255 [M−2H−rha-glu-rha−CO]− | 741 [M+H]+, 763[M+Na]+ |
|
| 6 | 9.81 | isorhamnetin-3- | 254, 354 | 769 [M−H]−, 314 [M−H−rha-glu-rha]−, 285 [M−2H−rha-glu-rha−CO]− | 771 [M+H]+, 793[M+Na]+ |
|
| 7 | 10.28 | kaempferol-3- | 265, 348 | 593 [M−H]−, 284 [M−H−rha-glu-rha]−, 255 [M−2H−rha-glu-rha−CO]− | 595 [M+H]+, 617 [M+Na]+ |
|
| 8 | 10.47 | isorhamnetin-3- | 254, 354 | 623 [M−H]−, 314 [M−H−rha-glu-rha]−, 285 [M−2H−rha-glu-rha−CO]− | 625 [M+H]+, 647 [M+Na]+ |
|
| 9 | 11.24 | isorhamnetin-3- | 254, 354 | 623 [M−H]−, 314 [M−H−rha-glu-rha]−, 285 [M−2H−rha-glu-rha−CO]− | 625 [M+H]+, 647 [M+Na]+ |
|
| 10 | 12.55 | unknow | - | - | 679 [M+H]+, 701 [M+Na]+ |
|
| 11 | 16.42 | unknow | - | - | 621 [M+H]+, 643 [M+Na]+ |
|
| 12 | 16.87 | 2α,12β-dihydroxy-7,15–isopimardiene–18–oic-acid | - | 333 [M−H]− | 335 [M+H]+ |
|
| 13 | 17.71 | unknow | - | - | 621 [M+H]+ |
|
| 14 | 20.27 | 2α,15S,16-trihydroxy-8(14)–isopimarene–18–oic-acid | - | 351 [M−H]−, 387 [M+Cl]− | 353 [M+H]+ |
|
| 15 | 36.87 | unknown | - | - | 274 [M+H]+ |
|
| 16 | 11.79 | unknown | - | 513 [M−H]−, 365, 315 | - |
|
| 17 | 12.71 | afzelin | 264 | 431 [M−H]− | 433 [M+H]+, 455 [M+Na]+ |
|
| 18 | 16.05 | unknown | - | 349 [M−H]− | - |
|
| 19 | 22.00 | unknown | - | 331 [M−H]−, 119 | - |
|
| 20 | 24.93 | unknown | - | 413 [M−H]−, 331, 119 | - |
|
| 21 | 26.07 | Quercetin-3,3′-dimethyl ether | 254, 352 | 329 [M−H]−, 301[M−dimethyl ether]− | - |
|
| 22 | 26.87 | unknown | - | 329 [M−H]−, 215 | - |
|
| 23 | 29.02 | unknown | - | 464 [M−H]−, 411, 329 | - |
|
| 24 | 37.58 | unknown | - | 391 [M−H]−, 325, 243 | - |
|
PT: Pollen typha; FT: Faeces trogopterori; - : not confirmed.
Figure 2The scores plot obtained from MarkerlynxTM analytical results in positive mode (A) and negative mode (B).
Figure 3The variation trends of fragment ions intensity of identified compounds from three samples of AESS (◊) , VESS (□) and Vinegar (∆). (a) typhaneoside. (b) quercetin-3-O-(2G-α-L-rhamnosyl)-rutinoside. (c) isorhamnetin-3-O-neohesperidoside. (d) quercetin-3-O-neohesperidoside. (e) kaempferol-3-O-neohesperidoside.